- Home
- SPB vs VRDN Comparison
SPB vs VRDN Comparison
Compare SPB & VRDN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | SPB | VRDN |
|---|---|---|
| Founded | 1906 | 2006 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Medical Specialities |
| Sector | Miscellaneous | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.8B | 2.1B |
| IPO Year | 1994 | 2014 |
Fundamental Metrics
Financial Performance| Metric | SPB | VRDN |
|---|---|---|
| Price | $88.10 | $31.19 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 8 | 17 |
| Target Price | ★ $98.57 | $41.69 |
| AVG Volume (30 Days) | 333.0K | ★ 2.8M |
| Earning Date | 11-12-2026 | 11-04-2026 |
| Dividend Yield | ★ 2.12% | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 1.01 | N/A |
| Revenue | ★ $3,802,100,000.00 | $5,706,000.00 |
| Revenue This Year | $1.81 | $6.01 |
| Revenue Next Year | $1.04 | $316.34 |
| P/E Ratio | $88.09 | ★ N/A |
| Revenue Growth | ★ 20.86 | N/A |
| 52 Week Low | $53.21 | $13.18 |
| 52 Week High | $99.06 | $34.29 |
Technical Indicators
Market Signals| Indicator | SPB | VRDN |
|---|---|---|
| Relative Strength Index (RSI) | 59.83 | 82.69 |
| Support Level | $85.13 | $17.84 |
| Resistance Level | $94.25 | N/A |
| Average True Range (ATR) | 2.92 | 1.50 |
| MACD | 0.85 | 0.72 |
| Stochastic Oscillator | 61.77 | 94.64 |
Price Performance
Historical ComparisonAbout SPB Spectrum Brands Holdings Inc.
Spectrum Brands Holdings Inc is consumer products and home essentials company. The company is a supplier of consumer batteries, residential locksets, residential builders' hardware, grooming products and personal care products. The company manages the businesses in product-focused segments; Home and Personal Care, which generates maximum revenue; Global Pet Care; and Home and Garden. The company manufactures, markets and distributes its products globally in the North America, Europe, Middle East & Africa, Latin America, and Asia-Pacific. It generates maximum revenue from North America.
About VRDN Viridian Therapeutics Inc.
Viridian Therapeutics Inc is a clinical-stage biopharmaceutical company that engages in developing multiple product candidates to treat patients who suffer from thyroid eye disease. The company is developing two anti-IGF-1R product candidates, veligrotug for intravenous (IV) administration and elegrobart (formerly VRDN-003) for subcutaneous (SC) administration, to treat patients with TED. Our most advance program, veligrotug, is a differentiated humanized monoclonal antibody targeting IGF-1R intravenously administered for the treatment of TED.